DARMSTADT, Germany, February 26, 2018 /PRNewswire/ --
Not intended for U.K./U.S. based media
- First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in Argentina - Mavenclad has shown sustained clinical efficacy for up to 4 years with a maximum of 20 days of oral treatment over 2 years
Merck, a leading science and technology company, today announced that the Argentinian Administration of Medicines, Food and Medical Technology (ANMAT), has approved the registration of MAVENCLAD(R) (cladribine tablets) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. This marks the first approval for MAVENCLAD(R) in Latin America and following local regulatory processes, the product is expected to be available in the coming months.
(Logo: http://mma.prnewswire.com/media/472778/Merck_Logo.jpg )
"Having a new MS treatment approved in Argentina is very motivating," said Dr. Jorge Correale M.D., the Head of Neuroimmunology and Demyelinating Diseases at the Institute for Neurological Research Dr. Raul Carrea. "Mavenclad allows the patient's immune system to go through a selective immune reconstitution, similar to a reset, and the treatment mechanism is simple because it does not require frequent administration or monitoring."
MAVENCLAD(R) is the first oral short-course treatment to provide efficacy across key measures of disease activity in patients with highly active relapsing MS, including disability progression, annualized relapse rate and magnetic resonance imaging (MRI) activity. The approval of MAVENCLAD(R) is based on more than 10,000 patient years of data with over 2,700 patients included in the clinical trial program, and up to 10 years of observation in some patients. The clinical development program included data from three Phase III trials, CLARITY,, CLARITY EXTENSION and ORACLE MS, the Phase II ONWARD study; and long-term follow-up data from the 8-year prospective registry, PREMIERE. The efficacy and safety results of these studies allowed for a full characterization of the benefit-to-risk profile of MAVENCLAD(R).
"We are pleased the Argentinian Administration of Medicines, Food and Medical Technology has approved Mavenclad," said Rehan Verjee, Chief Marketing and Strategy Officer at the Biopharma business of Merck. "Our goal is to ensure fast access to patients who may benefit from this innovative therapy and we will be working with payers on obtaining reimbursement as a next step."
MAVENCLAD(R) is a selective immune reconstitution therapy, which simplifies treatment administration by giving patients just 2 short annual courses of tablets with a maximum of 20 days of treatment over 2 years providing a lasting treatment benefit up to 4 years. MAVENCLAD(R) works by selectively targeting B & T lymphocytes followed by a distinct pattern of lymphocyte reconstitution, without continuous suppression of the immune system.
In patients with high disease activity, post hoc analyses of the two-year Phase III CLARITY trial, demonstrated that MAVENCLAD(R) reduced the annualized relapse rate by 67% and the risk of 6-month confirmed expanded disability status scale (EDSS) progression by 82% versus placebo. As demonstrated in the Phase III CLARITY EXTENSION study, no further MAVENCLAD(R) treatment was required in Years 3 and 4. The comprehensive dataset has informed the posology and monitoring requirements. The most clinically relevant adverse reactions were lymphopenia and herpes zoster. Lymphocyte counts must be assessed before, and during, treatment with MAVENCLAD(R). MAVENCLAD(R) is contraindicated in certain groups including immunocompromised patients and pregnant women.
The approval for MAVENCLAD(R) in Argentina follows marketing authorizations in the EU, Canada, Australia and Israel. Merck plans additional filings for regulatory approval in other countries, including the United States.
About MAVENCLAD(R) MAVENCLAD(R) (cladribine tablets) is approved in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein, Iceland, Isreal and Argentina for the treatment of highly active relapsing multiple sclerosis (RMS). MAVENCLAD(R) is approved in Canada and Australia for the treatment of relapsing-remitting multiple sclerosis (RRMS). MAVENCLAD(R) is a short-course oral therapy that selectively targets lymphocytes thought to be integral to the pathological process of relapsing MS (RMS). MAVENCLAD(R) is currently under clinical investigation and not yet approved for the treatment for any use in the United States.
The clinical development program for MAVENCLAD(R) includes:
- The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of MAVENCLAD(R) as a monotherapy in patients with RRMS. - The CLARITY extension study: a two-year Phase III placebo-controlled study following on from the CLARITY study, designed to evaluate the safety and efficacy of MAVENCLAD(R) over an extended administration for four years. - The ORACLE MS (Oral Cladribine in Early MS) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of MAVENCLAD(R) as a monotherapy in patients at risk of developing MS (patients who have experienced a first clinical event suggestive of MS). - The ONWARD (Oral Cladribine Added ON To Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled study designed primarily to evaluate the safety and tolerability of adding MAVENCLAD(R) treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy. - PREMIERE (Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Studies) study: interim long-term follow-up data from the prospective registry, PREMIERE, to evaluate the safety and efficacy of MAVENCLAD(R)
The clinical development program of MAVENCLAD(R) in MS comprises more than 10,000 patient years of data with over 2,700 patients included in the clinical trial program, and more than 10 years of observation in some patients.
About Multiple Sclerosis Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.